

**Table 1 Patient characteristics classified by age**

Variable	Age < 75 years (n=38)	Age ≥ 75 years (n=9)	p values
Median (range) age, years	62(37-74)	77(75-84)	< 0.0001
Male/female, %	76/24	90/10	0.4073
Hypertension, n(%)	20(53)	6(67)	0.4463
Diabetes mellitus, n(%)	8(22)	2(22)	0.9386
Smoking history, n(%)	21(55)	5(56)	0.8467
Prior nephrectomy, n(%)	15(39)	4(44)	0.7847
ECOG PS, n(%)			
0	21(55)	3(33)	
1	9(24)	5(56)	
≥2	6(16)	1(11)	0.2073
Missing (unknown)	2(5)	0(0)	
Risk factors based on MSKCC data, n(%)			
0 (favorable)	4(11)	0(0)	
1-2 (intermediate)	21(55)	8(89)	
≥3(poor)	11(29)	1(11)	0.2161
missing	2(5)	0(0)	
Common site of metastasis, n(%)			
Lung	21 (55)	6 (67)	0.5338
Bone	11 (29)	3 (33)	0.7959
Lymph nodes	10 (26)	3 (33)	0.6722
Histology, n(%)			
Clear cell	19(50)	6(67)	
Others	3(8)	0(0)	0.3384
Missing (untraced or unknown)	16(42)	3(33)	
Initial doses of sunitinib, n(%)			
50 mg			
4 weeks on, 2 weeks off	27(70)	5(56)	
2 weeks on, 1 weeks off	3(8)	0(0)	
37.5 mg			
4 weeks on, 2 weeks off	6(16)	3(33)	0.1483*
2 weeks on, 1 weeks off	0(0)	1(11)	
25 mg			
4 weeks on, 2 weeks off	1(3)	0(0)	
2 weeks on, 1 weeks off	1(3)	0(0)	
Relative dose intensity, %			
median	75.0	68.8	0.7559
mean±SD	72.5±19.4	70.4±15.9	0.8105
Clinical outcome of sunitinib treatment, n(%)			
Continuing sunitinib	3(8)	0(0)	
Discontinuing sunitinib	35(92)	9(100)	0.3837
Reason for discontinuation (n=42)			
Lack of efficacy	17(44)	6(67)	
Progressive disease	16(41)	5(56)	
Stable disease with increasing tendency	1(3)	0(0)	
Death	0(0)	1(11)	0.5019
Adverse events	15(40)	3(33)	
Others	3(8)	0(0)	

All statistical analysis was carried out except for missing data. Mean and median relative dose intensity (%) was calculated during the first 6 weeks of treatment. \*50mg vs ≤37.5mg; p= 0.1787

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; MSKCC, Memorial Sloan-Kettering Cancer Center; SD, standard deviation